文献速递类风湿关节炎

接受甲氨蝶呤背景治疗的类风湿关节炎患者中,加用来氟米特或他克莫司与TNF抑制剂的感染风险比较:一项基于人群的队列研究

Infectious risk of add-on leflunomide or tacrolimus versus TNF inhibitors among patients with rheumatoid arthritis receiving background methotrexate: A population-based cohort study.
PubMed 文献 · Semin Arthritis Rheum · 2022-04-28

基于韩国国民健康保险服务数据库的队列研究,比较接受甲氨蝶呤背景治疗的类风湿关节炎患者中,来氟米特与他克莫司分别对比TNF抑制剂的严重感染风险。主要结局为严重细菌、机会性及带状疱疹感染的复合终点。经倾向评分细分层加权后,来氟米特对比TNFi的HR为1.03(95%CI 0.89-1.22),他克莫司对比TNFi的HR为0.91(95%CI 0.77-1.08),均无显著差异。

要点

  • 来氟米特对比TNFi的严重感染HR为1.03(95%CI 0.89-1.22),无显著差异。
  • 他克莫司对比TNFi的严重感染HR为0.91(95%CI 0.77-1.08),无显著差异。
  • 带状疱疹感染发生率(每100人年3.70-4.27)超过严重细菌感染(1.12-1.36)的3倍,机会性感染相对罕见(0.11-0.23)。

核心结论

  • 在接受甲氨蝶呤背景治疗的类风湿关节炎患者中,来氟米特对比TNFi以及他克莫司对比TNFi的严重感染(即严重细菌、机会性及带状疱疹感染)风险均未见显著差异。

研究设计与样本

  • 使用韩国国民健康保险服务数据库开展的队列研究,纳入启动TNFi、来氟米特或他克莫司的类风湿关节炎患者。
  • 在72,516例接受甲氨蝶呤的类风湿关节炎患者中,识别出3,336例TNFi启动者、11,122例来氟米特启动者和5,136例他克莫司启动者。
  • 两个研究队列分别为:10,992例来氟米特启动者经倾向评分细分层加权于1,623例TNFi启动者,以及5,126例他克莫司启动者经倾向评分细分层加权于2,521例TNFi启动者。
  • 应用倾向评分细分层(PSS)和加权调整混杂,使用Cox比例风险模型估计风险比(HR)和95%置信区间(CI)。

主要发现

  • 主要结局为任何严重感染的复合终点,包括严重细菌感染、机会性感染和带状疱疹感染;次要结局为主要结局的各单独组分。
  • 带状疱疹感染的发生率(每100人年3.70-4.27)超过严重细菌感染(每100人年1.12-1.36)的3倍,机会性感染相对罕见(每100人年0.11-0.23)。
  • 来氟米特对比TNFi的任何严重感染PSS加权HR为1.03(95%CI 0.89-1.22)。
  • 他克莫司对比TNFi的任何严重感染PSS加权HR为0.91(95%CI 0.77-1.08)。
  • 次要结局分析显示一致的结果。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To compare infectious risk between leflunomide versus TNF inhibitors (TNFi), and between tacrolimus versus TNFi among rheumatoid arthritis (RA) patients receiving methotrexate (MTX). METHODS: Using Korea National Health Insurance Service database, we conducted a cohort study on RA patients initiating TNFi, leflunomide, or tacrolimus. The primary outcome was any serious infections defined as a composite endpoint of serious bacterial, opportunistic, and herpes zoster infections. Secondary outcomes were individual components of the primary outcome. Propensity-score fine-stratification (PSS) and weighting were applied to adjust for confounding. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox proportional hazard models comparing leflunomide versus TNFi, and tacrolimus versus TNFi. RESULTS: Among 72,516 RA patients receiving MTX, we identified 3,336 TNFi initiators, 11,122 leflunomide initiators, and 5,136 tacrolimus initiators. Two study cohorts were 10,992 leflunomide initiators PSS-weighted on 1,623 TNFi initiators and 5,126 tacrolimus initiators PSS-weighted on 2,521 TNFi initiators. The incidence rate per 100 person-years of herpes zoster infection (3.70-4.27) was beyond 3-times that of serious bacterial infection (1.12-1.36), but opportunistic infection was relatively rare (0.11-0.23). The PSS-weighted HR [95% CI] for any serious infection was 1.03 [0.89-1.22] comparing leflunomide versus TNFi, and 0.91 [0.77-1.08] comparing tacrolimus versus TNFi. Analyses on the secondary outcomes showed consistent results. CONCLUSION: In this nation-wide cohort study, we did not find a significant difference in the risk of serious infections (i.e., serious bacterial, opportunistic, and herpes zoster infections) between leflunomide versus TNFi, and between tacrolimus versus TNFi among RA patients receiving background MTX.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Shin A, Lee JH, Ha YJ, et al. Infectious risk of add-on leflunomide or tacrolimus versus TNF inhibitors among patients with rheumatoid arthritis receiving background methotrexate: A population-based cohort study. Semin Arthritis Rheum. 2022. PMID: 35567808. doi:10.1016/j.semarthrit.2022.152019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。